Company intelligence / Profile preview

Breye Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Breye Therapeutics has initiated a Phase 1b/2a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and early biological activity of its lead oral small molecule drug danegaptide in patients with diabetic macular edema. Danegaptide has demonstrated robust non-clinical efficacy and safety in over 500 participants from previous studies. The company also develops an oral P2X7 receptor antagonist for AMD and other retinal vascular diseases

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

danegaptide

Partnerships

Golgi Neurosciences Srl – collaboration on the P2X7 receptor antagonist program

Beyond the preview

Go deeper on Breye Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breye Therapeutics.

Explore the full profile